Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
16.33
-0.13 (-0.79%)
Official Closing Price
Updated: 4:10 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus
March 06, 2025
Via
Benzinga
Is SoundHound AI Stock a Buy Now?
March 05, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
February 24, 2025
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Via
Benzinga
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
February 20, 2025
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
February 18, 2025
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent...
Via
Benzinga
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
February 10, 2025
Via
Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
February 16, 2025
Via
The Motley Fool
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
February 10, 2025
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
MarketBeat Week in Review – 02/03 - 02/07
February 08, 2025
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
World Trade
Exposures
Artificial Intelligence
Interest Rates
Tariff
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
January 30, 2025
Via
Benzinga
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
January 30, 2025
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
January 27, 2025
Via
Benzinga
Neurocrine Biosciences Reports Mixed Q4
February 07, 2025
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Via
The Motley Fool
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
February 03, 2025
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?
Via
MarketBeat
NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
February 02, 2025
Discover the latest trends with last week's worst-performing large-cap stocks, including Manhattan Associates' steep decline following reduced financial guidance and the broader impact of China's...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Teva Pharmaceutical Stock Is Sinking Today
January 29, 2025
Via
The Motley Fool
Peering Into Teva Pharmaceutical Indus's Recent Short Interest
January 27, 2025
Via
Benzinga
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
January 29, 2025
TEVA earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
January 29, 2025
Via
Benzinga
Exposures
Fossil Fuels
Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday?
January 29, 2025
Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET.
Via
Benzinga
Topics
Economy
Government
Exposures
Interest Rates
Political
Stocks Scatter As Investors Prepare For Fed Remarks
January 29, 2025
Stocks are mixed this afternoon, as investors await an interest rate update from the Federal Reserve's first policy meeting of 2025.
Via
Talk Markets
Topics
Economy
Stocks / Equities
Exposures
Interest Rates
Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings
January 29, 2025
Via
Benzinga
Teva Pharmaceutical Posts Lower Revenue. Stock Slips.
January 29, 2025
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.
Via
Investor's Business Daily
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
January 29, 2025
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,...
Via
Benzinga
Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 29, 2025
Via
Benzinga
Earnings Scheduled For January 29, 2025
January 29, 2025
Via
Benzinga
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
January 28, 2025
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 27, 2025
Via
Benzinga
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug
January 23, 2025
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.